Investigating the Acceptance and Performance of Low Energy Audio Streaming in Nucleus 8 and Kanso 3 Sound Processors by Experienced Cochlear Implant Users

计划入组 20 人 · 首次发布于 2025 年 12 月 4 日

Hearing Outcomes With the Nucleus® 8 Sound Processor and Nucleus® 7 Sound Processor in Adult Veteran and Non-veteran Cochlear Implant Recipients

计划入组 26 人 · 首次发布于 2026 年 5 月 12 日

Clinical Performance of the Osia 3 Sound Processor Compared With the Osia 2 Sound Processor in Adult Osia Implant Users

计划入组 12 人 · 首次发布于 2024 年 3 月 29 日

SPI-128 (Sound Pharmaceuticals)

Oxybenzone(Meijer)

C₁₄H₁₂O₃

BE-3-3-3-3

Nucleus Network

Australia

Nucleus Network Ltd.

Australia

Sound Financial Bancorp

United States

Cochlear Receives FDA Approval for World's First Smart Cochlear Implant with Upgradeable Firmware

Phase 3 HOPE Trial Tests Novel Light-Sound Therapy Device for Moderate Alzheimer's Treatment

Sound Pharmaceuticals' SPI-1005 Demonstrates Efficacy in Meniere's Disease Phase 3 Trial